Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
-
Market Cap
63.91M
Enterprise Value
71.09M
Income
-1.10M
Sales
60.66M
Book/sh
0.28
Cash/sh
0.31
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
214
IPO
Jun 15, 1992
P/E
-
Forward P/E
-
PEG
-
P/S
1.05
P/B
16.42
P/C
14.66
P/FCF
-
EV/EBITDA
197.47
EV/Sales
1.17
Quick Ratio
1.03
Current Ratio
1.03
Debt/Eq
2.82
LT Debt/Eq
2.60
Option/Short
Yes / Yes
EPS (ttm)
-0.08
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
40.02% -
Sales past 3/5Y
3.33% 7.68%
EPS Y/Y TTM
-136.61%
Sales Y/Y TTM
6.65%
EPS Q/Q
3.16%
Sales Q/Q
8.84%
Insider Own
56.62%
Insider Trans
0.00%
Inst Own
18.36%
Inst Trans
-46.92%
ROA
-3.46%
ROE
-29.83%
ROIC
-7.89%
Gross Margin
47.69%
Oper. Margin
-1.54%
Profit Margin
-1.82%
SMA20
-3.92%
SMA50
-5.94%
SMA200
-18.01%
Trades
Shs Outstand
13.92M
Shs Float
6.04M
52W High
8.31 -44.74%
52W Low
4.52 1.59%
Volatility
2.44% 3.69%
ATR (14)
0.17
RSI (14)
38.00
Beta
0.46
Rel Volume
0.00
Avg Volume
9.76K
Volume
0
Perf Week
-3.33%
Perf Month
-2.10%
Perf Quarter
-7.05%
Perf Half Y
-23.22%
Perf YTD
-33.55%
Perf Year
-31.97%
Perf 3Y
-16.06%
Perf 5Y
-51.92%
Perf 10Y
162.38%
Prev Close
4.59
Price
4.59
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$12.00
Implied Upside
+161.3%
Analysts2incl. previous ratings
Rating Distribution2 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 12, 2024Upgrade
CCraig Hallum
Hold → Buy$6+30.7%
Nov 18, 2019Initiated
TThe Benchmark Company
Speculative Buy
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ACKERMAN JOELDirectorOct 15 '26Option Exercise1.6069,794111,6701,126,333Oct 16 12:45 PM
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Executive ChairDr. Ronnie Morris M.D.
CEO & DirectorMr. Robert Brainin
Chief Financial OfficerMr. David Barry Miller M.B.A.
Chief Operating OfficerDr. Maria Mancini Ph.D.
Executive Vice President of GrowthDr. Marianna Zipeto Ph.D.